SPT-300

SPT-300 (GlyphAllo) is Seaport Therapeutics' oral prodrug of allopregnanolone, a brain-calming neurosteroid, now in a Phase 2b trial for major depressive disorder (BUOY-1, NCT07065240) [1]. A prodrug is a molecule the body converts into the active drug after absorption; here, that active drug is allopregnanolone, the same neurosteroid delivered intravenously as Sage/Biogen's brexanolone (Zulresso) and taken orally as their zuranolone (Zurzuvae, approved for postpartum depression). Seaport's twist is a triglyceride-mimetic (Glyph) prodrug that hitches a ride on fat-absorbing lymph vessels in the gut, routing absorption through the lymphatic system rather than the portal vein and bypassing the first-pass liver metabolism that has hobbled prior oral allopregnanolone formulations [2]. If the pharmacology translates into a clean, durable antidepressant signal in a general MDD population, SPT-300 becomes a real challenger in a market where standard SSRIs remain slow and modestly effective and where zuranolone has struggled to secure a broad MDD label.

SPT-300 is a novel investigational compound in Phase 2b, currently recruiting in the BUOY-1 trial for MDD with or without anxious distress (NCT07065240, target n=360) [1]. It carries no publicly disclosed breakthrough therapy, fast track, or orphan designation. Seaport, spun out of Sage/PureTech veterans and backed by Arch Venture, General Atlantic, Sofinnova, and PureTech, went public in 2025 (Nasdaq: SPTX) and reported approximately $427 million in cash and equivalents at the end of Q2 2026, with runway guided into 2029 [3][4]. That comfortably covers BUOY-1 readout without a forced financing. The compound's underlying Glyph prodrug technology and human PK were published in Science Translational Medicine in March 2026, demonstrating oral bioavailability via lymphatic transport in animals and healthy volunteers and describing GlyphAllo as the first triglyceride-mimetic prodrug to achieve therapeutically relevant drug levels in humans [2]. A supportive Phase 1 driving-simulation trial in healthy volunteers reported positive topline results in 2026, with additional driving-simulation data expected in H2 2026 [9]. Seaport has guided BUOY-1 topline for H1 2027 [4].

GABA-A receptors are the brain's main brake pedal. When GABA (an inhibitory neurotransmitter) binds them, chloride flows into neurons and quiets their firing. Allopregnanolone is a naturally occurring steroid the body makes from progesterone that sits at a separate site on the GABA-A receptor and cranks up that braking action, a positive allosteric modulator (PAM). In postpartum depression, the drop in allopregnanolone is acute and biologically well documented, tied to the withdrawal of progesterone after delivery, and this is the setting where Sage validated the class with brexanolone (IV, approved 2019) and zuranolone (oral, approved 2023 for PPD) [5]. In general MDD the picture is softer: chronically reduced allopregnanolone has been observed in some studies but the causal direction is not established, and neurosteroid GABA-A PAMs remain a plausible rather than proven mechanism outside the peripartum window. The mechanism has strong genetic and pharmacological support at the target level: GABRA1 is the canonical alpha-1 subunit forming most synaptic GABA-A receptors [6], and Open Targets links GABRA1 to major depressive disorder with an evidence score of 0.67. The unresolved question is not whether neurosteroid GABA-A PAMs work acutely (brexanolone and zuranolone proved they do) but whether an oral, well-absorbed version produces a durable enough effect in general MDD to beat placebo in a registrational-quality trial. Zuranolone actually received a Complete Response Letter from FDA for its MDD application in August 2023, with the agency citing insufficient evidence of effectiveness [5], and that is the specific shadow SPT-300 has to escape. Simpson et al. reported in Science Translational Medicine that GlyphAllo was generally well-tolerated across single- and multiple-ascending oral doses from 70 to 1000 mg and produced therapeutically relevant plasma allopregnanolone concentrations, the first triglyceride-mimetic prodrug to do so in humans; specific bioavailability and half-life values are in the paper [2].

BUOY-1 (NCT07065240) is a Phase 2b, randomized, double-blind, placebo-controlled monotherapy study in adults with MDD, with or without anxious distress, targeting 360 participants [1]. The primary endpoint is change from baseline to Day 42 in the Hamilton Depression Rating Scale-17 (HAM-D-17) total score, the workhorse antidepressant endpoint that most MDD trials use [1]. The 6-week active-treatment window is longer than the 14-day dosing arc Sage used for zuranolone, which is a deliberate design choice: regulators and clinicians have been skeptical of the durability of short-course neurosteroid effects, and a 42-day endpoint reads out on whether benefit persists through continuous dosing. Whether BUOY-1 includes a formal off-drug follow-up window to characterize durability after dosing stops (the true commercial differentiator) is not clearly disclosed in the current ClinicalTrials.gov record and is worth watching for on next protocol amendment. The anxious-distress stratification is commercially and scientifically motivated: GABA-A PAMs have obvious mechanistic reasons to help anxious patients, and MDD with anxious distress is a large, poorly served subpopulation. Risks in the design: no active comparator (only placebo), so a positive result answers 'better than nothing' rather than 'better than sertraline'. There is also no disclosed biomarker or genetic stratification, which is a genuine gap given how heterogeneous MDD is.

Our model estimates a 4% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

The dominant efficacy risk is placebo response. Antidepressant trials routinely see placebo HAM-D improvements of 8 to 10 points, and neurosteroid trials have been particularly vulnerable to shrinking effect sizes as they moved from severe, biologically defined populations (postpartum depression) to broader MDD. Zuranolone hitting in PPD and receiving a CRL for MDD is the specific cautionary tale [5][7]. Safety risk is on-target CNS depression: sedation, dizziness, and somnolence dose-limited zuranolone and forced a bedtime-only label. If SPT-300's improved PK produces higher CNS exposure, tolerability could constrain the dose that actually shows efficacy; the Phase 1 driving-simulation data are early positive evidence against a sedation-heavy profile but do not settle the question at therapeutic exposures over weeks [9]. There is also a food-effect and drug-interaction question inherent to lymphatic-transport prodrugs (absorption depends on co-ingested lipids) that the Phase 2 program will need to characterize. Execution risk is real: Seaport is running a 360-patient study across multiple sites, and enrollment pace for MDD trials has been slow industry-wide since 2023. Commercial risk is the tallest hurdle even in a win scenario. Zurzuvae, approved for PPD in late 2023, generated roughly $72 million in U.S. net product revenue in 2024 (a small fraction of consensus expectations at approval) [10], reflecting narrow PPD labeling, payer restrictions, prescriber hesitancy around a Schedule IV controlled substance, and the food-effect dosing requirement. Any oral neurosteroid entering MDD will face payer skepticism versus generic SSRIs and would need a clean 2-point HAM-D delta plus a differentiated profile (rapid onset, durable effect, tolerability, permissive food dosing) to command pricing.

Worth watching, with a specific question in mind. The signal that would change the story is BUOY-1 hitting the Day 42 HAM-D-17 endpoint with a placebo-adjusted delta of at least 2 points and a clean tolerability profile, particularly no meaningful sedation signal. That would validate the Glyph lymphatic-transport prodrug thesis in a large indication and put Seaport on a path to a registrational Phase 3 with real commercial optionality. A miss, or a hit with a small delta buried under sedation, and this program looks like a slightly better-absorbed zuranolone (which itself is doing about $72M/year in a restricted PPD label [10]), and that is not enough. Seaport's approximately $427M cash position provides runway into 2029 [4], comfortably past the BUOY-1 readout guided for H1 2027, so investors are not being asked to price in a financing risk before data. Check back on Seaport's next 8-K, quarterly call, and the H2 2026 driving-simulation topline for enrollment progress and safety colour [3][9]. Seaport's broader pipeline provides some diversification: SPT-320 (GlyphAgo), a Glyph prodrug of agomelatine in Phase 1 for generalized anxiety disorder, and SPT-348 (Glyph-2-Bromo-LSD), a preclinical non-hallucinogenic LSD analog for treatment-resistant depression and related indications [11]. But SPT-300 is the lead program and BUOY-1 is the defining readout for the company's valuation over the next 12 to 18 months.